The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of it's AI-enabled ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms ...

BofA lowered the firm’s price target on Tempus AI (TEM) to $48 from $60 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel ...

Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas ...

Norges Bank acquired a new position in Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the 4th quarter, according to the ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

(RTTNews) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation.

NASDAQ:TEM opened at $42.12 on Thursday. The stock’s 50 day moving average price is $56.19 and its two-hundred day moving average price is $50.92. Tempus AI has a 12-month low of $22.89 and a 12 ...